HC Wainwright Increases Earnings Estimates for AC Immune

AC Immune (NASDAQ:ACIU) – Equities researchers at HC Wainwright increased their FY2026 earnings estimates for AC Immune in a research report issued on Monday, May 4th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.84) per share for the year, up from their previous estimate of ($0.87). The consensus estimate for AC Immune’s current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for AC Immune’s FY2028 earnings at $1.11 EPS and FY2029 earnings at $1.56 EPS.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. The firm had revenue of $1.40 million during the quarter, compared to analyst estimates of $0.33 million.

ACIU has been the subject of several other research reports. Jefferies Financial Group reissued a “buy” rating and issued a $7.00 price objective on shares of AC Immune in a research report on Friday, March 13th. BTIG Research reissued a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research report on Monday. Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.50.

AC Immune Price Performance

AC Immune stock opened at $3.01 on Wednesday. AC Immune has a 52-week low of $1.51 and a 52-week high of $4.00. The firm has a fifty day moving average of $2.94 and a 200-day moving average of $3.09. The firm has a market capitalization of $306.33 million, a P/E ratio of -3.67 and a beta of 1.65. The company has a quick ratio of 1.02, a current ratio of 0.87 and a debt-to-equity ratio of 0.11.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. EFG International AG bought a new position in AC Immune during the 4th quarter valued at $41,000. Private Advisor Group LLC bought a new position in AC Immune during the 3rd quarter valued at $48,000. Sei Investments Co. bought a new position in AC Immune during the 2nd quarter valued at $51,000. Goldman Sachs Group Inc. boosted its stake in AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after acquiring an additional 5,920 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new position in AC Immune during the 3rd quarter valued at $63,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.